NCI-2022-06899

Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC

This open-label Phase 3 study is comparing two treatments for advanced lung cancer: MK-7684A, a combination of Vibostolimab and Pembrolizumab, and Durvalumab. These medications work by helping the immune system fight cancer cells. The study aims to determine which treatment is more effective and safer for individuals with advanced lung cancer that cannot be surgically removed.

Phase 3: A phase 3 clinical trial is a large-scale study designed to assess the effectiveness and safety of a new medical treatment or approach compared to a standard treatment

open-label: Patients know which treatments are being given to them

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05298423

Clinical Trial Site: Sinai

To see all available clinical trials click here.